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U&M&~. This analysis sought tn evaluate the clinical chrr- 
actcristin and outcune in heart failure with mild systolk dys- 
fUllCtiOlS. 
lkckgmd AMmugb heart failure with mild systolic dysfunc- 
tim occurs commonly, this i6 an understudied area hecause 
dinkal trials have usual!, exctuded patients with ejection fraction 
>35%. 
Methods. The 422 patientswith kft ventricular ejection fraction 
~35% were compared with 172 with a kft ventricular ejection 
fraction ~35% in the Vasodilatw in Heart Failure Trial W-Hem 
l), whereas in V-HeFf-II 554 patients with a left vmtrkular 
qjectbn fktiun 35% were rompared with 218 patients witb a 
left vmtriclllrr ejection fraction >35% for mortality and clinical 
m For a left vmtrkdar ejection fraction >35%, treatment with 
b~aLuiw/isosorbide dinitrate was compared with praz.osin and 
placebo therapy ia V-Hem l, and bydraIazine/isasorbide dinitrate 
was compared with eaabpril in V-HeFf II for mortality, clinical 
ccmrse aad change in pbysiologk variables: ejection fraction, 
plasma norepiwpbriac levels vmtricular tacbycardia and ecbc 
ardiographic variabkss. 
Res&. Is bot& studies, patients with a left ventricular ejection 
Mi ~35% diPrred prbwipaHly ia hypertensive history, higher 
Left ventricular systolic dysfunction is a common manifestation 
of clinical heart failure and has been drmonstratcd to corrclatr 
with mortality risk. Consequently, clinical trials usually have 
excluded patients with well pregrvcd Icft ventricular systolic 
function (1-S). although this group may represent a substantial 
portion of the population exhibiting the clinical syndrome 
(h-8). Indeed, the paucity of data on this population has led an 
expert panel to exclude such patients from the recommended 
clinical guidelines for management of heart failure (9). 
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functional capacity and radiugraphic and echocardiographk car- 
diac dimension from patients with a kfl vmtricular ejection 
fraction 535%. and plasma ncrepinepbrine levels difervd in 
V-HeFf II (p < 0.011. Patients with a ltft ventricular ejection 
fraction >3S% had a lower cumulative mortality than those ritb 
a Ieft vrntriculor ejection fraction CJSQ Ip < 0.00011 and [KS 
frequent hospital admissions for heart failure (p C 0.014. 
V-Hem I; p < 0.005, V-Hem II). Altbougb cumulative mortality 
and morbidity did not direr hetween treatment grumps in 
V-Hem 1, cnalapril decreased oven~ll nwiality versus bydrala- 
zineliwsorbide dinitrate fp 4 0.@35) in V-HeFT II. For physidogk 
variables in V-HeFf II. malrpril decrrssed ventricular tacbycar- 
dia at follow-up fp < 0.05I. 
Con&.rLw. In V-HeFf, heart failure with mild systdic dys- 
function was associated with diferent cbarPcteristics and a IIKIR 
favorable prognosis than karl failure with more severt systolic 
dysfunction. Enalapril decreased overall mortality and sudden 
death compared with hydraluine/iscwrbide dinitrste. Prospci- 
tire trials are needed to address therapy for heart failun with 
mild systolic dysfunction. 
(J Am Call Canlid 1996;27:642-9) 
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In the Vasodilator Heart Failure Trials (V-HcFT) (IO,1 I). 
patients with preserved left ventricular systolic function (left 
vcntriculdr cjcction fraction >45% ) were not excluded if they 
exhibited radiographic evidence of an enlarged left ventricular 
cad-diaMic diamctcr along with reduced peak excrci.w oxy- 
gen consumption. We previously repnted on the subgroup in 
V-HeFT I who entered the study with an ejection fraction 
>45% (12). Because an ejection fraction S3.58 or even lower 
has been an entrance criterion in several recent multicenter 
trials (l-4). we have now analyzed in both V-Hem I and 
V-Hem II the clinical characteristic%. prognosis and response 
to therapy in those patients with an ejection fraction >3SQ at 
randomization. These data add to previous mortality results 
from V-Hen (13) and should provide further insight into the 
implications of the selection criteria utilized in recent trials and 
offer clues to the response to therapy in this understudied 
patient population. 
Methods 
Male patients w’ere screened for participation in the study 
OR the basis of a history of heart failure or documenUon of 
left ventricular enlargement or dysfunction by chest radiogra- 
phy. echocardlogrrphy or radionuclide vsntriculography. The 
specific ventricular imaging requirement t,,r entF was one of 
the following: a radiographic ca:diothoracic ralirj NSS. an 
cchwardiographic left ventricular end-diaktohc diam;ter .:2.7 
cm/m’ booty surface area or radionuchdc left ventricdiir 
ejection fraction ~U.45. In addition, patients were eligible for 
entry only if they had reduced maximal exercise tolerance. IX 
was defined as a measured peak oxygen consumption (Vo:) 
<2S ml/kg per min during a progressive hicycle ergometer 
exercise test. 
Further details of these trials have been published previ- 
ously (NJ.1 I). Pertinent to this analysis. gated radionuclide 
angiography was performed to determine left ventricular cjec- 
tion friction. A Halter monilor was applied during the last 
prrrandomization hospital visit lo provide an average of 4 h of 
electrocardiographic (ECG) monitoring for measurement of 
ventricular arrhythmia> on a dual-channel full-disdosurc for- 
mat in a core laboratory (Veterans A5ain Medical Center. 
Washington, D.C.). I,hrrricularpra,lorlrre blurs were defined as 
any beat of ventricular origin faster than the sinus rate. 
Ventrhlar tachwmf~u was defined as ~3 ventricular prema- 
ture beats. In patients entering V-Heff II, a venous blood 
sample was ohtained for measurement of ncurohormone Ievel~ 
(core laboratory. Minncapcblis. Minnesota) after the patient 
had rmted supine for at least 30 min. 
Patients were randomized fo receive placehI (Jr active drug: 
Full doses of the vawdilator regimens in V-H&T 1 were either 
prazosiu 5 mg four times daily or the combination of hydrala- 
zinc ?; mg dnd i:tijl;ibidc :ini:;aK XI mg four times drily. The 
V-Hem II participants received either the same hydralazind 
isosorbide dinitratc regimen or enalapril IO mg twice daily. 
Drug administration was double-blind. All patients were srud- 
ied for the duration of the trial and for a minimum of h months 
or until death. 
AII death reporis with local classification and supportive 
documentation were rrvicwed hy a central committee without 
knowledge of treatmrnt assignment. When necessa?. the 
mechanism of ,ieath was rcclassificd by the central committee 
IO make the c:as\itication of deaths consistent Icross all 
centers. 
Statistical methods. Baseline measurements were re- 
stricted to the test done at the time of randomization. The 
twesample I test was used to compare mean values for 
continuous variahles for plasma norepinephrine cutoff points 
and ctassifications. The Cox proportional hazards regression 
rnodcl (14) was used to determine the significance of ejection 
fraction, peak Vo,. cardiothoracic ratio. ventricular tachycar- 
dia. plasma norepinephrine levels and treatment as multivari- 
ate predictors of survival. Kaplan-Meier cumulative mortality 
cures were plotted lo the end of follow-up to descn&e the 
trends in monality over time in each of the risk categories. 
Survival cunc’c were compared by the icbg-rank test i 15). 
Results 
In V-Hen I. ti2 patients were enrolled from March IYXO 
until June IYG. Of the SYJ patients with a bawlinr left 
ventricular ejection fraction measurement. Q-1 had an ejection 
fraclion S3Sci. and 172 had an jc’ction fraction >35%. 
In V-HrFT II enrollment was SO4 patients from March 
lY11h to Scptemhr IYYU. Of Ihc 772 patients with baseline 
data. 5S4 had an ejection fraction ~35~;. and 218 patients had 
an c:cction fraction >3Zci. 
Left wtat~ ejectioa ftactiotr 535% vefsus >Wk. 
fIusr/irtc* charucreristics. The bacclinc characteristics in V- 
Hem l (Tahlc !) indicate that patients with a left ventricular 
ejeclicn fraction >35 ‘; had a mean left ventricular ejection 
fraction uf 46.4’i (range -%? t3 865 ) compared with 23X 
(range h’;i to 35C; ) for paticnic with a left ventricular ejection 
fraction 535’i The higher cjectiun fraction group more 
commonly had a tGztorv of hypertension hut less commonly 
had a histo? of cr*;onar) artery disease and previous myocar- 
dial infarction. Patienlt with a left ventricular ejection fraction 
>3Sci also had higher peak VEIL and higher supine systolic 
blood pressure hut lower supine heart rate. Their mean 
cardiothoracic ratio and ccbrardiographic left ventricular 
internal diastolic dimension were alu, smaller. In view of the 
mul:iplr comparisons. statistical signiticance between groups 
was dssesud a1 p ( 0.111. 
In V-Hem II. pattents with a left ventricular ejcrtion 
fraction ~35ci had a mean left ventricular ejection fraction of 
2.~~; (range UC;; to 355). whereas those with a left ventricular 
ejection fraction >3SQ had a mean left ventricular ejection 
fraction of 43.2% (range .36C to 865). Comparrd with Ihe 
Tabk 2. Dislrihution of Basclinc Variables in V-HcFT II for 
Patients With Left Ventricular E~uc~ion Fraction ~35~~ ;Inl’ ;3?‘1 --- 
LVEF 
EF (5) 
Age WI 
Hiwy of HTN 
Mcan PVC Ill1.h 
Cwptelr 
Miu Vu, (ml,% per mm) 
SBP wpinc (mm Hgb 
HR supine (kats mm) 
CTR(6) 
LVIDD (cmd 
PNE tpgirnl) 
‘p < 0.01 Data prwnkd arc mean ~luc z SD LIT numtw I’c) of pawn!-. 
PNE = plwna rwrrpincphnnc: PVC = Premature vrntrddr cnnlracticm~: 
nhcr abhrcvktionr a* in Tahlc I. 
group with a left ventricular ejection fraction ~35?;, the group 
with preserved left ventricular systolic function was older and 
more commonly had a history of hypertension. They also had 
a higher peak Vo?, as well as a higher supine systolic blood 
pressure, lower supme heart rate, smaller mean cardiothoracic 
ratio and left ventricular internal diastolic dimension. They 
also had tower plasma norepinephrine concentrations (Table 
2). Slatistic?l significance was again set al p < (MI. Presence of 
ventricular arrhythmias (premature ventricular contractions 
>lO/h and couplets) differed at p < 0.04. 
Mortu/iry. The mortal@ of patients with a left ventricular 
ejection fraction ~35% was significantly lower than those with 
a left ventricular ejection friction ~35% in both V-Hem I and 
V-Hem II. In V-Hem I, 208 of 422 patients with a left 
ventricular ejection fraction ~35?$. died during the study 
(annual mortality rate [AMR] 20.7%) compared with 51 of 172 
patients with a left ventricular ejection fraction >35% (AMR 
10.2%). 71e cumulative mott.dity ratios differed significantb 
(p < IMMI~) (Fig. 1). By mechanism of death, for a left 
ventricular ejection fraction ~35% 42% were classified as 
sudden death and 34% as pump failure: for a left ventricular 
ejection fraction >35%, 51% of deaths were classified as 
sudden and 18% as pump failure. 
In V-Hem II, 220 of 554 patients with a left ventricular 
ejection fraction 535% died (AMR 14.76). whereas 49 of 218 
patients with a left ventricular ejection fraction >356 died 
(MR 7.8%). There was a statistica! difference in cumulative 
mortality (p < O.ooOl) (Fig. 2). For a left ventricular ejection 
fraction =35%, 28% of deaths were classified as sudden and 
30% as pump failure, whereas for a left ventricular ejection 
fraction >35%. 33% were identified as sudden deaths and 20% 
as pump failure. 
A multivariate model for patients with a left ventricular 
ejection fraction >35% using variables predictive of mcrtality 
in the overall V-Hem II cohort indicated that peak Vy (p = 
O&t). cardiothoracic ratio (p = 0.007) and plxma norepineph- 
Fiiun 1. Cumuliltiw illl~CW4! morlality cutvc5 for V-HCFT I com- 
p;lring paricnrh with IcR ventricular ejection fraction (LVEF) ~3Yi 
and :-*,wr 
rine lerels (p = tt.04) (in strata >700 pgiml) were predictive of 
mortaiib. Treatment (p = 0.07) and ventricular arrhythmia 
(p = 0.M) had less independent prognostic impact, but the 
power of the multivariate model was decreased by the smaller 
sample with all variables present. Lef! ventricular ejection 
fraction did not have independent predictive value in the 
analysis ot patients with measurements >35%. 
,MorC.&. In V-Hem I, a greater proportion of patients 
with a left ventricular ejection fraction ~-357~ were admitted to 
the hospital for heart failure rhan patients with a le;t venlric- 
ular ejection fraction >35% (2G.8% vs. 15.6%. p = 0.014). 
Similarly in V-Hem II. proportionally more patients with a 
left ventricular ejection frxtion 135% were admitted to the 
hospilal for heart failure than those with a left ventricular 
ejection fraction >35% (21.7% vs. l2.8%, p = 0.005). However 
overall hospital admissions did not differ in either V-HeFT I 
(59.8% ys. 59%. p = NS) or V-Hem II (59.4% M. 619, p = NS). 
In V-Hem I, myocardial infarction occurred in 13 of 409 
patients with a left ventricular ejection fraction ~35% and 3 of 
IH7 patients with a left ventricular ejection frarlion ~35% 
(p = NS). For V-Hem II, of thou with a left ventricular 
F@r 3. Cumulative alkausc mortality in V-HcFT I comparing 
rr;xmcfit with plxchn (PL). prazcek rnd the hydrai~inr~iuxclrhidc 
dinitratr (HYD-IS0 [Hl]) nimhinarion for Icfl ventricuiar qccricm 
fraction >Wi. 
ejection fraction 535%. 44 of 554 patients experienced myo- 
cardial infarction compared with IS of ZIR with a left ventric- 
ular ejection fraction >339 (p = NS;. 
Tbenpeutie mpors~ with left veutr;culnr cjeckinr Wiaa 
>35%. Monol$. In V-HeFT 1. patients with a left ventricular 
ejection fraction >35%., baseline characteristics did not differ. 
Overall. 14 of SO patients treated with hydralazinelisosorbide 
&nitrate died (AMR 9.49) co.mpared with 19 or 72 in the 
placebo group (AMR 9SQ) and 1Y of S? in the prazosin group 
(AMR 12.3%). Cumulative mortality did not differ (p = NS) 
(Fig. 3). There was no di5erence between the groups hy 
mechanism of death (Table 3). 
In V-HeFT If. patients with a left ventricular ejection 
fraction >35%. the baseline characteristics differed only in a 
larger left ventricular internal diastolic dimension in the ena- 
lapril group (p < 0.01). For a left ventricular ejection fraction 
>3S%. 1% of 103 patients treated with enalapril died during the 
study (AMR 5.7%). and 31 of I IS patients died while treated 
with hydralazinelisosorbide dinitrate (AMR 9.G). The cumu- 
lative mortality was statistically reduced in enalapril-treated 
patients (R < 0.035) (Fig. 4). By mechantsm of death. sudden 
death was decreased by enalapril (p < 0.01). but pump failure 
deaths were infrequent and did not differ (p = NS) (Table 3). 
MorGfity. In V-HcFT I, there was no difference in the 
proportion of patients admitted to the hospital for congestive 
heart failure in the treatment groups (23.1’? prazosin. 16? 
Fire 4. CumularI\;e allcdur mortaltt! In V-H&-T II comparing 
treatment with rnalapril (El with hydralvinr iunorbltic dinitrarc 
(HYD-IS0 [HI]) for lcfr \:nrricular cjcl?ion fraction 1-35’;. 
hydral~azine.‘isosnrh~de dinitrate. lS.3c~ placebo. p = NS) or 
for any cause (61-S? prazosin. SK hydr;lazine/isosort~idc 
dinitrate. S9.75; placebo. p = NS). In V-HeFT II. the propor- 
tion hospitalized was similar for congestive heart failure for 
enalapril and hydralazine isosorbide dinitrate (11.7% vs. 
13.X?, p = NS) or for any cause (61.79 vs. 60.X. p = NS). 
For myocardiai infarction in V-HeFT 1. there were two es*ents 
for prazrrin-treated patients. no events reprted for hydralazine. 
isosorbide dinitrate-treated palicnts. and one event for placc- 
bo-treated patients. In V-Hem II. h oi 103 enalapril-treated 
patients and 9 of t Ii hyJrzlazine!isosorbide dinitratc-treated 
patients evriewtd rnyocardial infarction (p = NS). 
pb~ys*l~ en prints, kR vcntrknlar ejtcth fmtii 
>3SE w- L ,C <riL..d fur serial change in ejection fraction. 
plasma noreprnephrine. echocardiographic dimension and 
ventricular tachycardia only in V-HeFT If because: therapies 
ditfered statistically for mortality in the left ventricular et&on 
fraction >35Q group only in that study. 
When measured at follow-up. there was no significant 
change in ejection fraction (Fig. 5) or plasma nurepinephrine 
levels (Fig. 6) between the enalapril group and the hydralazinel 
isosorbide dinitrate group. Echocatdiographic variables 
showed no di5erence at 6 months between cnalapril and 
hydrJazine!isos&ide dinitrate except for a decrease in L+T- 
tolic posterior wail thickness in enalapril-treated patients (p < 
0.01) iTable 4). 
T&k 3. Treatment Effect t’y Mechanism of Death for Lft Vcmrtcutar Ejecrivn k&n ;.I% 
All ciluw 
sudhl 
Pump fahrc 
Change in ventricular khycardia wa\ analyzed b! chary 
from haselinc t~cauu the prevalcncc of ha4inc ventricular 
tachycardia ditkrcd hetwccn groups. lkrr *.w u statkticall) 
significant decreau, in the cnalapril group at I3 wceb and 2 
years (p < CM). hut ~0 significant change from h&inc was 
seen in the hydralazin&osorhidc dinitratr group (Fig. 7). 
Discwsion 
The currcnc analysis indic&s tbt ;I *ignificclnt proponion 
of patients with cstahlishcd heart failure c.m have rmh mild 
systolic dysfunaion (295 in V-IicfT I. Wr in V-Hcl% II). 
l&e patients ditkr in haselk characteristics :md have ;1 
more favorable prognosis than those with scvcrc cv\Mic 
dysluncrion. Although mortality reduction was not &I with 
either prazosin or the hydralazine,ksorhi~ dinitrarc cornhi- 
nation compared with plxrh) in V-HclT I. cnalapril de- 
IIgmw 6. Ctnnprkt of snahpril and hydralslinc,iunorbirk dtni- 
ItaW (HYDIW) wxtttrwnt in V-H&T II on change in plwna 
rn~pirhphrir~ (PNE) lewl~ (pgml) in pa~icn~s with lcfr wnrriatlar 
cjedon frartion (LVEF) -.Wr a ? nwnlhs and I. 2. 3 and 4 +n. 
LTCW~ mortality nbmparcd with the vandilutor comhinatiun 
in V-IkFT II. 
Left vcnlricle ejection fmrtion >35%. Comparison with 
prrvious Jala ik difficult. FM cxamplr. Sctaro rt al. ( 16) studied 
an older patient group with heart failure and a mean left 
ventricular cjcction fraction of hl%: they tound an all-cause 
5.5vear mortality of W:. The tncrall cumulative motlality for 
up 10 M months for kft ventricular cjrctkn fraction >35% in 
V-HeiT I was Alan 4j“i. Therefore. although these studies 
dlffcrcd in importrml characteristics. the long-term mortalit) 
W;I\ similar. In thr prcviou\ ;malysk of V-Hem 1 with left 
vrntricular cjcaion fraction :45/r hy (‘ohn and Johnson (12). 
the annual mortality rate was W”i. contrasting with IO.?“i for 
left ventricular ejection fraction >3SCi in the current study. In 
contrast. the annual mortality rate for left ventricular ejxtion 
fraction -.Wi in V-Hem I was X7’Y. 
fin 7. Change in vrnrricul.tr whwtrdb (VT) from twwlinc for 
rndapril (El-~rcakd and hyJrullirir&owrtdr dinitratc (HYDKW 
(till)-trctitd patients with MI vcmricular cjcction fractlr)n >.W( in 
V-HCFT II. Nubws sdrr ppb xc numkr of paficnts. VPB = 
wGcular pwmalurtz kalk 
~ 
l 
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The baseline characteristics and clinical course for patients 
with mild systolic dysfunction (left ventricular ejection fraction 
>3SC) suggest that they might be considered as a separate 
clinical entity from left ventricular ejection fraction <Wi for 
examination of pathophysiologic mechanisms and response to 
therapy. The mechanism of heart iailure for these patients is 
uncertain. Patients with severe valvular regurgitation might 
have heart failure with a normal ejection fraction. Although 
primary valwlar dysfunction was an exclusion criterion for 
V-HeFT. Doppler examination was not part of the protocol. 
and therefore. a contribution of significant valvular dysfunction 
undetected by physical examination cannot be excluded. A 
history of hypenension occurred more commonly in the mild 
systolic dysfunction patients. and :herefore. diastolic dy3func- 
tion could have been part of the clinical syndrome. Left 
ventricular hypenrophy WIF\ commonly present, but Dopp!er 
measurements were not available to assess the role of myoccar- 
dial compliance and ventricular filling characteristin. Cat- 
echolamincs were lower in patients with left ventricular cjcc- 
tion fraction >35% compared uith those with left ventricular 
ejection fraction 535%. reflecting the hypothesis advanced by 
Benedict et al. (17) that a decreased ejection fraction is a 
stimulus to elevate catecholamine ievels. However. catrchol- 
amine levels are higher than those reported for control pa- 
tients (18). also suggesting that, even with mild systolic func- 
tion. the presence of heart failure is asrociated with increased 
sympathetic activation. Myocardial &hernia can contribute to 
diastolic dysfunction. hut patients with active ischemia were 
excluded from V-HeFT by history and exercix test. 
In terms of mechanism of death. in both V-HcFT I and II. 
for patients with less severe leh ventricular dysfunction. sud- 
den death was the more common mechanism of death, and 
pump failure deaths were infrequent. Previous reports assess- 
ing the severity of heart failure by another means. New York 
Heart Association functiona! class. have also indicated that the 
relative incidence of sudden death is increased in patients in 
functional classes I and I! (SO3 to tXtOrr ) compared with those 
in classes HI and IV (20% to 30%) f 19-21). Hence. patients 
with preserved left ventricular systolic function or those who 
are less symptomatic appear to be at greater relative risk for 
sudden death as opposed to pump failure death. 
TlIenpeQtie n!spomstwltb left remicmlatejeetll hctilm 
~3% Vasodilator therapy in heart failure has &en ass&- 
atcd with symptomatic benefit as well as improved survival. In 
V-HeFf I (It!). it was demonstrated that the combination of 
hydralazineiiscsotbide dinitrdte improved survival mmparcd 
with pfacebo. with an cvetall 28% reduction in total mortality. 
although that hrnefit was not seen in the subse; with mild 
systolic d@unction. I~X reiatively small numbers in this 
analysis cannot exclude the possibility that benefit might exist 
in a larger cohort. More extensive data exist concerning the 
survival benefit of angrotensin-convetting enzyme inhibitors. 
particularly in pwttp failure deaths. in Cooperative North 
Scandinavian Enalapril Survival Study (CONSENSUS) (1) and 
in Studtes of Left Ventricular Dysfunction (SOLVD) (3). 
The trials wparing an angiotensineonverting enzyme 
inhibitor with a vasodrlator combination of lrydral:rrinel 
isosorbide dinitrdtc all demonsIrarcd bertcfit from angioterain- 
converting enzyme inhibitors. In V-HefT II. cnalapril reduced 
mortalitv 95 at 1 _ - _ years cumparcd with the vauxlifarrr 
combination with the mortality reduction occurring in sudde.1 
deaths. Ihe mechanism of death result IS contrary to the 
SOLVD and CONSENSUS data. but diffcrrnt populations 
and classifications oi death make comparison d;fftcult. iurther. 
the comparison of enalapril in V-HeFf II is no: with pldcebo 
hut with a vasodilator combination of proven efficacy that 
similarlv reduced pump failure deaths. The latter explanation 
ia supported by Fonarow et :,I. (2). who found that captopril 
reduced mortality compareti with hydralazine and !hat the 
reduction lay enttrcly in su.fdrn death. A comparison with 
hvdralazine dots raise the isst,e of whether hydralazine. which 
has a minor direct myocardi.tl effect (‘.I). could increase the 
likzlih~ood of sudden detith; hcluc\dr. no such increase was 
wzen in \.‘-HeFf I (13). 
II; terms of patients with n.ild systolic dysfunction and heart 
failure, little data exist comparing specific agents. It was noted 
in SOLVD (3) that enalapril did not decrease mortality in 
patients with left ventricular ejection fraction of 305 to 35%. 
although no description of the characte&tin of those patients 
has been published. Ihew data art’ also difficult to compare to 
the current analysis. which had a left ventricular ejection 
fraction >Wi for inclusion and a mean Iefi ventricular 
ejection fraction of 46%. Further. as has been commented 
previously. the SOLVD patient group and placebo comparison 
repreunt important diaerences from V-HeFf. 
The enalapril reduction in mortality in the mild systolic 
dysfunction patients in V-HeFf was entirely in reduction of 
sudden deaths. It should be emphasized that many deaths in 
heart failure cannot be classified with certainty (e.g.. unwit- 
nessed deaths). and disagreement may alw exist on classifica- 
tion criteria and therefore on individual events (24). However. 
it is intuitive that patients with relativefy preserved leh ven- 
tricular fuKtion should be at low risk for pump failure death. 
In fact, the infrequency of pump failure deaths in this analysis 
makes assessment of eGcacy between treatment groups for this 
end point problematic. However. the favorable e&et on 
sudden death. coupled with the trend for a more fworable 
early serial change in ejection fraction with the hydtalazine- 
isowrbide dinitratc combination. makes possihk a nonvasodi- 
lator explanation for the enalaprif survival benefit. Enalapril 
patients did have :I.tenuated neurohomtonal stimulation up to 
I year in a manner and direction similar to the overall V-HeFT 
If study (25.5). hut as with ejection ftactio~r. the treatment group 
comparison in this analysis lacked suflicient powr heeauu of 
SIIIdli INUTIkB. TkrefOre. a COIWeIhg Cnz)me inflwIIc&? ofl 
mortality through a neurohormonal mechanism eanttot be 
excluded. Myrxardial hypertrophy might also influence mor- 
tality. but serial cchwrrdiographie measurements differed 
little between groups. Pn effect on diastolic function such as 
suggested by Pouleur e, al. (26) cannot be excl&d however. 
as mr measurements were not performed in V-HeFF. 
Myocardial infarction can strongly influence survival in 
heart failure. and SOLVD data (27) indicated that rnalapril 
decreased these: events. Howcvcr, myctirdial infarction\ were 
infrequent events in V-Hen, and no diffcrencc was ohservcd 
between treatment groups. 
The parallel reduction in ventricular (achjcardia and sud- 
den death .scen in this analysis was present in the overall 
V-Hem iI study (28). Previous smaller studies have indicated 
a reduction by angiotensin-converting enzyme inhibitors of 
ventricular arrhythmia including CUII.PICX forms (29-31). The 
parallel reduction in ventricular arrhythmias and sudden dcalh 
was also seen in the Sunival and Ventricular Enlargement 
(SAVE) Trial (32.33). which evaluated post-myocardial infarc- 
tion patients with left ventricrldr dysfunction. In contrast. no 
reduction in either ventricular arrhythmia (34) or sudden 
death (3) was sccen in SOLVD. although the Hoher suhstud) 
was relatively small and sudden death was an infrequent 
classification. 
The potential mechanism for arrhythmia reduction is un- 
clear. A recent analysis (35) of the overall V-HcFT II study 
indicated that nonsustain& ventricular tachycardia was asso- 
ciated with WOIW ventricular function. heart size and func- 
tional capacity and was not an independent predictor of 
mortality. This suggests that ventricular tachycardia mzy be a 
marker for a worse overall heart failure condition rather than 
a marker for electrical instahility. The implication of an 
arrhythmia suppression effect of an angiotensinconverting 
enzyme inhibitor is likely very different, for example. from that 
of a drugwith primary antiarrhythmic propertics. such as in the 
Cardiac Arrhythmia Suppression Trial (CAST) (3b), in that it 
may be a.wciated with improved cardiac function. However. 
the patients in this analysis have only mild systolic dysfunction. 
Therefore, the relation between the arrhythmia reduction 
caused by a change in cardiac function and ouIcomc in this 
population is uncertain. 
Swnmur)-. The available data indicate that enalapril rc- 
duces total mortality in mild systolic dysfunction compared to 
hydralazine/itl%de dinitrate and that a parallel reduction 
occurs in sudden death and ventricular tachycardia. 
SW& IimiMons. This analysis, although pan of two ran- 
domized double-blind studies is relrospeclive and therefore is 
best considered as hypothesis generating. Assumptions based 
on small numbers of events must be viewed with c&ion. and 
the assignment of mechanism of death is limited in many cases 
because pump failure and arrhythmia are often linked. End 
points that are not prospectively defined, such as myocardial 
infarction. may suffer from underreporting or overreporting. 
Data of follow-up measurements may alw be affected by 
regression to the mean, requiring cautious interpretation. 
Therefore, these data should not guide therapeutic decisions 
for hydralazine/iirbide dinitrate, prazosin or enalapril in 
heat? failure patients with mild systolic dysfunction but rather 
should provide a basis for design of a future trial. 
caoduiops. In V-Hem, heart failure wirh left ventricular 
ejection fraction >35% defines a group of patients with 
differrut characteristics and a more favordble prognosis than 
lefl ventric&r ejection fraclion 135%. Enalapril reduced 
mortalit\ comparrd to the vasodilator combination of 
hvdralaz&iu)sorhidc dinitrate. and this cffcct appeared prin- 
cipally in deaths classilicd 1% sudden. The cause of the cnalapril 
mortalily reduction in left ventricular cjcction fraction >35% 
remains ohscure. although a reduction in ventricular arrhylh- 
rniti from baseline was noted. This very promising result. in a 
patirnt group with littlc previous data. should prompt a 
prorpcctivc trial to assess treatment for this large segment of 
the heart failure population. 
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